Morphine promotes renal pathology in sickle mice

Marc L Weber1
Derek Vang2
Paulo E Velho2,3
Pankaj Gupta4
John T Crosson5
Robert P Hebbel2
Kalpna Gupta2

1Division of Renal Diseases and Hypertension, 2Vascular Biology Center and Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA; 3Department of Medicine, University of Campinas Medical School, Campinas, SP, Brazil; 4Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota and VA Medical Center, Minneapolis, MN, USA; 5Department of Lab Medicine Pathology, Hennepin County Medical Center, Minneapolis, MN, USA

Abstract: Patients with sickle cell disease (SCD) are often treated with opioids for severe pain. Although opioids are known to have renal-specific effects, their role in nephropathy in SCD remains unknown. Because a subset of patients receives opioids for long periods of time, we examined the influence of chronic morphine treatment on mice with pre-existing renal disease expressing varying amounts of sickle hemoglobin. Morphine treatment for 3–6 weeks resulted in a variety of defects in renal morphology observed using light and electron microscopy. Notably, morphine induced glomerular pathology, resulting in increased glomerular volume, mesangial expansion, mesangial cell proliferation, parietal cell metaplasia, podocyte effacement, and microvillus transformation. Cystic tubulopathy and hemeoxygenase-1 expression and activity were also increased in morphine-treated mice. Naloxone, a non-selective opioid receptor (OR) antagonist, ameliorated these effects. Functionally, the urine albumin to creatinine ratio was increased following acute as well as chronic morphine treatment. These results suggest that clinically relevant doses of morphine induce renal pathology and that OR antagonists may be effective for ameliorating morphine-induced renal disease.

Keywords: mesangial cell, morphine, nephropathy, pain, podocyte, sickle cell disease

Introduction

Sickle nephropathy is recognized as a devastating manifestation of sickle cell disease (SCD).1 Although the pathophysiology of sickle nephropathy is not completely understood, potential etiologic factors include the mechanical effects of red blood cell (RBC) sickling, hyperfiltration, oxidant-mediated damage, and unintended side effects related to medical therapies.2–4 Sickle patients commonly use opioids long-term due to “crises” and chronic pain treatment;5 these patients often require higher doses than those with other diseases due to alterations in drug pharmacokinetics and metabolism as well as increased renal clearance.6 Via opioid receptors (ORs), opioids induce kidney disease in rodents.7–9 Thus, opioids may exacerbate renal disease during SCD. However, the effect of opioid use on kidney disease remains unknown.

Opioids act via three well-defined G-protein coupled receptors (GPCRs): mu-, delta-, and kappa-opioid receptors (MOR, DOR, and KOR, respectively), as well as other undefined receptors. In addition to analgesia induction, opioids activate growth, survival, and cytoprotection via ORs in multiple cell types in peripheral organs and in the central nervous system (CNS).10–12 An association between morphine and renal disease was first identified more than three decades ago when heroin-associated nephropathy was recognized in chronic drug abusers, implicating morphine (a metabolite
of heroin) as a possible etiologic agent. Our previous study showed that chronic administration of morphine, a MOR agonist, in clinically relevant doses results in significant glomerular pathology, including mesangial growth, glomerular enlargement, and increased proteinuria in tumor-bearing and wild-type (WT) mouse kidneys. Earlier studies from other laboratories revealed that morphine directly stimulates mesangial cell, medullary interstitial cell, and fibroblast proliferation in vitro. These data indicate that morphine inadvertently promotes renal disease in SCD. We therefore examined whether morphine adversely affects renal morphology and function in the kidneys of transgenic sickle mice with the long-term goal of developing strategies for preventing, treating, or delaying nephropathy onset in SCD patients.

Materials and methods

Mice

All mouse studies were performed with prior approval from the Institutional Animal Care and Use Committee (#0806A37663).

We used three transgenic murine models expressing human sickle hemoglobin to determine whether the effect of morphine on the kidney is strain-specific and/or influenced by the variability of sickle hemoglobin expression. NY1DD mice exhibit a very mild (and non-hemolytic and non-anemic) phenotype, are homozygous for deletion of murine \( \beta \)-globin, and carry a single copy of linked transgenes for human \( \alpha \)- and \( \beta^s \)-globins. These mice have a C57BL/6 genetic background. WT C57BL/6 mice were used as controls for NY1DD. BERK mice are homozygous for knockout of both murine \( \alpha \) and \( \beta \) globins and carry a single copy of linked transgenes for human \( \alpha \) and \( \beta^s \) globins. Therefore, BERK mice express human \( \alpha \) and \( \beta^s \) globin chains (ie, human hemoglobin S), but no murine \( \alpha \) or \( \beta \) globins. These mice have severe disease resembling human sickle cell anemia, exhibiting hemolysis, reticulocytosis, anemia, extensive organ damage, and a shortened life span. hBERK1 mice are homozygous for knockout of murine \( \alpha \) globin, hemizygous for knockout of murine \( \beta \) globin, and carry a single copy of linked transgenes for human \( \alpha \) and \( \beta^s \) globins. hBERK1 mice express the globin chains human \( \alpha \), human \( \beta^s \), and murine \( \beta \) (human hemoglobin S and hybrid human mouse \( \beta \) hemoglobin) and show renal pathology. Both BERK and hBERK1 have the same mixed genetic background and can be bred as littermates. Control hemoglobin A (HBA)-BERK mice have the same mixed background as BERK and hBERK1, but exclusively express human \( \alpha \) and \( \beta^A \) globins (thus, normal human hemoglobin A), but no murine \( \alpha \) or \( \beta \) globins. Mice were bred in a pathogen-free facility, maintained under controlled environmental conditions (12-hour light–dark cycle, 23°C), and were genotyped and phenotyped using isoelectric focusing and, when necessary, real-time polymerase chain reaction to identify the transgene number.

Drugs and treatments

Sickle hemoglobin-expressing mice with pre-existing renal pathology and their controls were treated with vehicle (phosphate-buffered saline [PBS]) or morphine for 3 and 6 weeks, with or without coadministration of the OR antagonist naloxone. Injectable morphine sulfate and naloxone were obtained from Baxter Esidererle Healthcare (Cherry Hill, NJ) and Hospira Inc (Lake Forest, IL), respectively. Each day, mice were injected subcutaneously with increasing doses of pharmacological grade morphine (0.75, 1.4, 2.14, 2.8, 3.6, and 4.3 mg/kg/day in two divided doses during the 1st, 2nd, 3rd, 4th, 5th, and 6th weeks, respectively, which is equivalent to approximately 50–301 mg/70 kg human/day). Naloxone was used in a dose equivalent to 10 mg/70 kg/day. Sex- and age-matched mice were treated with PBS. Mice were treated for a total of 3 or 6 weeks, and euthanized at the end of treatment using CO\(_2\). Kidneys were excised, weighed, and processed for analysis.

Histology

Formalin-fixed, paraffin-embedded kidney sections were cut at 4 µm and stained with (i) Periodic acid–Schiff (PAS) stain and counterstained with hematoxylin, and (ii) hematoxylin and eosin (H&E) and analyzed by a renal pathologist in a double-blind manner. Images were visualized using a Zeiss AXIOPHOT microscope (Carl Zeiss Microscopy, LLC, Thornwood, NY) with a 10× eyepiece and a 40× or 100× objective. Photographs were acquired using an Olympus DP70 camera and 160ME digital camera interface using Olympus DP Manager version 3-11288 (Olympus Corporation, Tokyo, Japan).

Electron microscopy

Kidney sections were collected in 4% formaldehyde and 1% glutaraldehyde, washed in PBS, placed in osmium for 90 minutes, washed in acetone, embedded in epon, and dried overnight. One-micron-thin sections were stained with methylene azure II blue were evaluated using light microscopy to select blocks for electron microscopy. Selected blocks were cut in 500-nM thick sections using a diamond knife, placed on a wire grid, stained with uranyl acetate and lead citrate,
and evaluated on a JEM 1011 electron microscope (JEOL, Tokyo, Japan). Electron micrographs were acquired using the built-in camera.

**Glomerular volume measurement**
Morphometric analysis was performed on 4-µm PAS-stained kidney sections and based on the method of point counting as described previously.9 Thirty glomeruli were counted for each kidney. The area of the entire glomerulus, including the glomerular tuft, the urinary space, and the Bowman’s capsule was included for volume estimation.

**Urine albumin and creatinine**
Urine albumin and creatinine were analyzed using the Assay-Max Mouse Albumin ELISA Kit (catalog no EMA3201-1, AssayPro, St Charles, MO) and the Creatinine assay kit (Cayman Chemicals, Ann Arbor, MI), respectively, according to the manufacturers’ instructions.

**Northern analysis of heme oxygenase 1 (HO-1) mRNA expression**
HO-1 mRNA expression in the kidney was assessed using Northern analysis as described previously.20 Briefly, RNA was extracted from the kidneys using the Trizol method, separated on an agarose gel, and transferred to a nylon membrane. The membrane was hybridized overnight with a 32P-labeled human HO-1 cDNA probe. Densitometry of the autoradiogram was performed and standardized by factoring optical density of HO-1 with the optical density of the 18S rRNA. Optical density of the 18S rRNA was obtained from a negative of the ethidium bromide-stained nylon membrane.

**Measurement of renal HO activity**
HO activity was assessed by measuring the rate of bilirubin generation by microsomes prepared from kidneys as described previously.21 Briefly, microsomes were incubated with mouse liver cytosol (a source of biliverdin reductase), hemin (20 µM), glucose-6-phosphate (2 mM), glucose-6-phosphate dehydrogenase (4 U/mL), and NADPH (0.8 mM) for 90 minutes at 37°C in the dark. Bilirubin was extracted using chloroform; the difference in optical density (OD) at 464–530 nm (extinction coefficient, 40 mM/cm for bilirubin) was measured, and enzyme activity was determined (pmol-bilirubin formed/h/mg protein).

**Data and statistical analysis**
Data are expressed as the mean ± standard deviation (SD) or standard error of the mean (SEM). One-way analysis of variance (ANOVA) with Tukey’s post-test or Student’s t-test, as applicable, was performed using GraphPad Prism version 5.04 for Windows (GraphPad Software, Inc, La Jolla, CA). Because of unequal sample sizes and multiple groups, Tukey’s post-test was selected for analysis. Statistical significance was defined as P < 0.05.

**Results**

**Mouse models of kidney disease in SCD**
We used three transgenic mouse models exhibiting kidney abnormalities characteristic of human SCD and expressing varying levels of sickle hemoglobin (HbS). Mouse models used included hBERK1 (~26% HbS), NY1DD (~40% HbS), and BERK (~99% HbS).17–23 Age- and sex-matched control WT C57BL/6 mice (0% HbS) were on the same genetic background as NY1DD and HbA-BERK mice (0% HbS) were on the same mixed genetic background as hBERK1 and BERK (littermates). HbA-BERK mice express normal human HbA. hBERK1 mice were used, although these mice express lower levels of HbS because they develop kidney disease and pain.19,22–24 Morphine-induced renal pathology observed in this study in mice from different genetic backgrounds suggest that these effects are not influenced by the strains of the mice. Table 1 shows different transgenic mice, controls, and number of mice used in this study.

**Baseline kidney characteristics of mouse models and controls**
As described previously, transgenic sickle mice exhibited pathological abnormalities in kidney tissue as compared to their strain-specific background controls.17–19 HbA-BERK controls exhibited parietal epithelial cell (PEC) metaplasia in many glomeruli, which were larger compared to C57BL/6 controls (not shown) as we previously reported.9 Our previous study showed that the kidneys of untreated C57BL/6 mice showed no pathological abnormalities except for slight hypertrophy of PECs in males and vascular congestion.9 Although tubules in HbA-BERK kidneys were

---

**Table 1**

<table>
<thead>
<tr>
<th>Type of mouse</th>
<th>PBS</th>
<th>Morphine</th>
<th>Naloxone + morphine</th>
<th>Naloxone</th>
<th>Figure #</th>
</tr>
</thead>
<tbody>
<tr>
<td>NY1DD</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>1 and 6</td>
</tr>
<tr>
<td>hBERK1</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>2 and 6</td>
</tr>
<tr>
<td>HbA-BERK</td>
<td>6</td>
<td>6</td>
<td>None</td>
<td>None</td>
<td>2</td>
</tr>
<tr>
<td>BERK</td>
<td>6</td>
<td>6</td>
<td>None</td>
<td>None</td>
<td>3, 5, and 6</td>
</tr>
<tr>
<td>BERK</td>
<td>4</td>
<td>4</td>
<td>None</td>
<td>None</td>
<td>4</td>
</tr>
<tr>
<td>NY1DD</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>hBERK1</td>
<td>6</td>
<td>6</td>
<td>3</td>
<td>3</td>
<td>5</td>
</tr>
</tbody>
</table>

**Abbreviations:** HbA, hemoglobin A; PBS, phosphate-buffered saline.
more dilated compared to C57BL/6 kidneys, no vascular congestion was observed (not shown), revealing strain-specific variability.

**Morphine treatment alters the histology and ultrastructure of kidneys in sickle mice**

All mice were treated with increasing doses of morphine similar to those used in patients with SCD. Mice were treated with vehicle (PBS) or morphine for 3 (NY1DD) and 6 (hBERK1 and BERK) weeks. NY1DD and hBERK1 mice were also treated with or without coadministration of an OR antagonist, naloxone, for 3 and 6 weeks, respectively. The minimum 3-week treatment period was chosen based on our previous study showing that morphine-induced mesangial glomerular volume was optimum 3 weeks after morphine treatment in C57BL/6 mice.\(^9\)

**Light microscopy of transgenic NY1DD sickle mice kidneys**

Three weeks of morphine treatment induced glomerular expansion, tubular dilatation, and intraglomerular and peritubular congestion compared to mice treated with PBS (Figure 1). In the cortico-medullary region, sloughing of epithelial cells and loss of brush border was observed in some morphine-treated but not in PBS-treated mice (Figure 1D, green arrow). A higher magnification image from a morphine-treated mouse kidney shows increased juxtaglomerular cells and extremely high intraglomerular congestion (Figure 1E).

**Light microscopy of transgenic hBERK1 and HBA-BERK mice kidneys**

Morphine treatment of hBERK1 for 6 weeks led to alterations similar to those observed in morphine-treated NY1DD mice, except for tubular dilatation, which did not increase upon morphine treatment in hBERK1 mice. As described above, tubules of hBERK1 mice were more dilated than those of NY1DD mice at baseline, perhaps due to strain differences. Increased cellularity of mesangial and juxtaglomerular cells and PEC metaplasia resembling tubular epithelial cells were observed in hBERK1 mice treated with morphine as compared to mice treated with PBS (Figure 2A–D). Co-treatment with naloxone antagonized morphine-induced pathological changes, suggesting an OR-mediated mechanism (Figure 2C). Naloxone alone did not influence renal pathology in hBERK1 mice (Figure 2D). Control HbA-BERK mice expressing normal human hemoglobin also showed increased glomerular enlargement after 6 weeks of morphine treatment as compared to treatment with PBS (Figure 2E and F). These data suggest that morphine-induced pathology is independent of the strain of transgenic mice expressing sickle hemoglobin. Furthermore, mice did not develop a tolerance to the effect of morphine in the kidneys even after prolonged treatment for up to 6 weeks.

**Light microscopy of transgenic BERK mice kidneys**

Similar to NY1DD and hBERK1 mice, morphine treatment for 6 weeks resulted in glomerular and tubular changes in BERK mice (Figure 3). Morphine-treated mice show increased glomerular volume and extremely high PEC metaplasia as compared to PBS-treated BERK mice (Figure 3A, C and E, green arrows). Peritubular congestion was remarkably high in morphine-treated mice as compared to PBS-treated BERK mice (Figure 3B and D, black arrows). Morphine-induced tubular pathology showed epithelial cells sloughing off from the basement membrane, loss of brush border, and proteinaceous deposits (Figure 3C and D, yellow and turquoise arrows), suggesting tubular injury.
Electron microscopy of BERK mice kidneys

Electron microscopy revealed mild to moderate mesangial prominence, with a mild increase in mesangial cells, slightly increased foot process effacement, prominence of red cell fragments, and electron dense iron deposits in the kidneys of BERK mice treated with morphine for 3 weeks as compared to PBS-treated BERK mice (Figure 4). Foot processes, the mesangial region containing mesangial cells, and the mesangial matrix appeared to be normal in PBS-treated BERK mice (Figure 4A and B). Foot process effacement and marked microvillus transformation were accompanied by increased mesangial cell proliferation and mesangial matrix, resulting in an expanded mesangial area without evidence of immune complexes in the kidneys of morphine-treated mice (Figure 4C–E).

Morphine treatment significantly increased glomerular volume in mouse kidneys. Morphine treatment for 3–6 weeks led to significantly increased glomerular volume in the kidneys of HbS-expressing and HbA-BERK mice as compared to PBS-treated mice (Figure 5). Glomerular volume increased by 22% in NY1DD mice (P < 0.01) after 3 weeks of morphine treatment and by 26% and 22.5% in hBERK1 mice (P < 0.01) and BERK mice (P < 0.05), respectively, after 6 weeks of morphine treatment as compared to PBS treatment. Naloxone antagonized morphine-induced glomerular enlargement, suggesting an OR-mediated effect (Figure 5).

Morphine increases kidney weight in sickle mice

Mice did not show a significant gain or loss in body weight after morphine and/or naloxone treatment as compared to PBS-treated mice (data not shown). Fractional kidney mass
Morphine induces albuminuria

Treatment of NY1DD mice with morphine significantly increased urine albumin to creatinine ratios 24 h after treatment; these values remained increased over a period of 3 weeks (Figure 6B). These data suggest that renal histopathological alterations induced by morphine are associated with functional abnormalities in mice expressing HbS.

**Morphine increases heme oxygenase (HO) in the kidney**

HO-1 is upregulated in the kidneys of mice and humans with SCD, and chronic morphine increases HO in the spinal cord and kidney. Morphine treatment likely further increases HO as a stress response. We therefore examined the effect of chronic morphine treatment on HO activity and HO-1 mRNA expression in hBERK1 mouse kidneys. Treatment with morphine for 3 weeks resulted in a significant increase in HO activity and HO-1 mRNA in hBERK1 kidneys (P < 0.001 and 0.01, for activity and mRNA, respectively, versus PBS [Figure 7]). Similar effects were observed in control HbA-BERK kidneys, suggesting that chronic morphine treatment leads to increased HO activity in the kidneys, irrespective of sickle Hb expression in mice.

**Discussion**

Nephropathy is a major factor contributing to morbidity in SCD. The present study demonstrates that chronic exposure to morphine promotes renal injury in sickle mice. Additionally, our data show that chronic opioid exposure inadvertently leads to development of renal disease in non-sickle mice in the absence of underlying pathology. We also demonstrate that morphine impairs renal function, in part through histopathologic alterations in the glomerulus. Using two different strains of mice (NY1DD on C57BL/6) and BERK/hBERK1 (on mixed background), we reveal distinguishable features of morphine-induced strain-specificity in the kidney.

Opioids and their receptors were once thought to have an exclusive role in the CNS, but have also been identified to have activity in the kidney. While it is unclear whether increased MOR and KOR expression is a cause or consequence of renal disease, OR antagonism by naloxone suggests that morphine-induced renal effects are mediated by ORs.

Glomerular enlargement is thought to result in increased urinary protein excretion and to be a precursor of glomerular sclerosis. We observed increases in kidney weight, glomerular volume, and urinary albumin excretion in sickle mice exposed to morphine treatment. Additionally, glomerular epithelium is critically important in the development of
Figure 5 Morphine treatment increases glomerular volume. (A–C) Glomerular volume of NY1DD (A), hBERK1 (B), and BERK (C) mice treated with morphine and/or naloxone for 3 or 6 weeks as indicated. Note that morphine stimulates a significant increase in glomerular volume, which is abrogated by co-treatment with naloxone, although naloxone alone did not alter glomerular volume.

Notes: Each bar represents the mean ± SD of 3–6 mice/group; equal numbers of male and female mice were used except in one group (1 male and 2 females).

Abbreviations: MS, morphine sulfate; Nal, naloxone; PBS, phosphate-buffered saline; SD, standard deviation.

Figure 6 Morphine treatment increases kidney weight and urine albumin. (A) Kidney: body weight ratio of NY1DD, hBERK1, and BERK mice treated with morphine as indicated. (B) NY1DD mice were treated with morphine for 3 weeks. Urine was collected before beginning treatment and periodically following treatment.

Notes: Arrow indicates the start of morphine treatment. Morphine treatment showed a highly significant increase in urinary albumin excretion after one day of treatment, which was sustained throughout the 3-week treatment period as compared to baseline values before beginning treatment. BL refers to baseline measurements obtained before starting morphine treatment. *P < 0.001 or †P < 0.01, compared with BL. N = 6 mice (3 females and 3 males).

Abbreviations: MS, morphine sulfate; Nal, naloxone.
sickle mice, our data suggest that morphine exacerbates the underlying pathologic condition by contributing to glomerular pathology.

Podocytes regulate glomerular function by maintaining the filtration barrier between the capillaries and urinary space. Even localized podocyte injury induces stress on uninjured podocytes, glomerular endothelium, and mesangial cells, initiating a cycle of progressive glomerular disease. Consistent with increased albuminuria, morphine treatment resulted in podocyte effacement and microvillus formation, suggesting podocyte injury and disruption of glomerular filtration barrier in sickle mice. An increased number of podocyte microprojections was observed using SEM following one week of morphine treatment in rats.33

We also show that tubular damage was exacerbated in morphine-treated mice. These observations are consistent with chronic morphine-induced vacuolization of tubular cells and increases in blood urea nitrogen in the kidneys of Wistar rats. Furthermore, morphine-induced rheological changes in red blood cells led to the intra- and extra-glomerular capillary vascular congestion in the kidneys of mice treated with morphine. This may contribute in part to the observed glomerular enlargement.

Morphine inhibits the activity of glutathione reductase purified from human erythrocytes.34 This may lead to increased oxidative stress in tissues. In previous studies, we observed increased HO-1 activity in the kidneys of sickle mice with renal injury.35 HO-1 plays a protective role against cellular insults such as oxidative stress and heme protein-induced injury.35 Low concentrations of morphine were shown to increase proliferation and HO activity in glomerular epithelial cells in vitro.36 In the present study, increased HO activity and HO-1 expression in the kidneys of mice treated with morphine may have been due to increased oxidative stress and serves as a protective mechanism against morphine-induced renal injury. This is a novel finding which requires further investigation.

Clinical studies of sickle cell nephropathy show varying degrees of albuminuria, hyperfiltration, and an altered glomerular filtration rate.37 Variable use of opioids may be a contributing factor to physiologic and hematologic renal responses in SCD. Analgesic nephropathy is recognized as a problem, although clinical attention has focused almost exclusively on the roles of non-steroidal anti-inflammatory drugs (NSAIDs) in acute renal failure, development of edema, and hypertension.38 Because these opioids are frequently used at high doses, are started at an early age,
and administered repeatedly throughout life, the clinical implications of our data are significant considering the high incidence of nephropathy in SCD. Therefore, clinical studies are required to directly assess the association of opioid use and nephropathy in patients with SCD.

Authors’ contributions
MLW performed experiments and assisted with writing the manuscript; DV performed urine analysis; PEV interpreted data and wrote the manuscript; JTC and PG analyzed and interpreted histopathology and electron microscopy data; RPH conducted genotyping, provided mice, and gave advice regarding editing of the manuscript; KG conceived, designed, and supervised the study and analyzed and interpreted data as well as edited the manuscript.

Acknowledgments
We thank Mariya Faroouqi, Tasneem Poonawala, Karl A Nath, Anthony Croatt, Stefan Kren, and Janet Parker for technical assistance. This work was funded by NIH grants, RO1 HL68802, HL103773, HL68802-06S1, HL68802-7S1 (to KG) and PO1 HL55552 (to RPH).

Disclosure
The authors report no conflicts of interest in this work.

References


